0001209191-22-011338.txt : 20220218
0001209191-22-011338.hdr.sgml : 20220218
20220218164711
ACCESSION NUMBER: 0001209191-22-011338
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220216
FILED AS OF DATE: 20220218
DATE AS OF CHANGE: 20220218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pang Phillip
CENTRAL INDEX KEY: 0001787370
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39083
FILM NUMBER: 22653531
MAIL ADDRESS:
STREET 1: C/O VIR BIOTECHNOLOGY, INC.
STREET 2: 499 ILLINOIS STREET, SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vir Biotechnology, Inc.
CENTRAL INDEX KEY: 0001706431
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 812730369
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 499 ILLINOIS STREET
STREET 2: SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-906-4324
MAIL ADDRESS:
STREET 1: 499 ILLINOIS STREET
STREET 2: SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-16
0
0001706431
Vir Biotechnology, Inc.
VIR
0001787370
Pang Phillip
C/O VIR BIOTECHNOLOGY, INC.
499 ILLINOIS STREET, SUITE 500
SAN FRANCISCO
CA
94158
0
1
0
0
Chief Medical Officer
Common Stock
2022-02-16
4
M
0
5000
1.53
A
97777
D
Common Stock
2022-02-16
4
S
0
5000
31.54
D
92777
D
Common Stock
2022-02-17
4
S
0
3009
31.9308
D
89768
D
Stock Option (Right to Buy)
1.53
2022-02-16
4
M
0
5000
0.00
D
2028-04-27
Common Stock
5000
52591
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.
Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.
/s/ Howard Horn, Attorney-in-Fact
2022-02-18